Published in Cancer Weekly, March 7th, 2006
"This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of UFT/LV and oxaliplatin in patients (pts) with MCRC who had not received prior chemotherapy for metastatic disease. Between February 2002 and October 2002, 64 patients received UFT (R) 300 mg/m2/day and LV 90 mg/day from day 1 to day 14 combined with oxaliplatin 130 mg/m2 on day 1, every 3 weeks," researchers in France reported.
"All patients were evaluable for safety analysis and 58 of 64 patients were eligible for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.